This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Biosimilars: approval

A biosimilar is a biologic product that is approved based on a demonstration that it is highly similar to an already-approved biologic product, known as the reference medicine1

The aim of biosimilar approval is to demonstrate high similarity in terms of structure, biological activity, efficacy, safety and immunogenicity1

By demonstrating biosimilarity, a biosimilar can rely on the safety and efficacy experience gained with the reference medicine, avoiding unnecessary repetition of prior clinical trials of the reference medicine1

If a biosimilar is highly similar to the reference medicine, and has comparable safety and efficacy in one indication, those data can be extrapolated to other indications already approved for the reference medicine1

Extrapolation is a well-established scientific principle used routinely when biologics with several approved indications undergo major changes to their manufacturing process1
  • Extrapolation is not automatic and must always be supported by scientific evidence generated in robust comparability studies1,2 
  • In most cases, clinical studies are not repeated for all indications and changes are approved based on quality and in vitro comparability studies1
  • However, sufficient scientific justification needs to be provided for extrapolating clinical data to support a determination of biosimilarity for each condition of use for which approval is sought1,2
Development and approval of a biosimilar progresses in a step-wise manner1HeaderKickerHeader of this CTA card goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…

Button

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:

EMA/European Commission. Biosimilars in the EU: information guide for healthcare professionals. 2019. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed May 2023.FDA. Scientific considerations in demonstrating biosimilarity to a reference product. April 2015. Available at: https://www.fda.gov/media/82647/download. Accessed May 2023.Biosimilars
Clinical evidence

INFLECTRA® infusion therapy (CT-P13) has been evaluated across 5 randomised controlled trials

 Learn more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0145 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024